Kathryn Elizabeth Packman

This inventor holds 11 USPTO granted patents and 16 published patent applications, plus 1 CIPO patent and 7 EPO patents. Top assignees: Hoffmann-La Roche Inc., Janssen Pharmaceutica Nv, Roche Glycart Ag. Active years: 2014-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kathryn Elizabeth Packman. Retrieved from https://idiyas.com/inventor/kathryn-elizabeth-packman

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 11 (Patent Applications = 16)

% Patents Active = 81.8

CIPO Patents = 1 (Patent Applications = 7)

EPO Patents = 7 (Patent Applications = 16)

Average Co-Inventor Count = 5.8

ph-index = 3

Forward Citations = 33(Granted Patents)

Location History:

Bloomfield, NJ (US) (2014 - 2023)
Newton, MA (US) (2018 - 2023)

Company Filing History:

7 out of 5,026

Hoffmann-La Roche Inc.

patents

2 out of 2,101

Janssen Pharmaceutica Nv

Years Active: 2014-2026

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12622910 - Inhibitors of Bruton's tyrosine kinase and methods of their use (2026-05-12),

2. 11738003 - Method for administration (2023-08-29),

3. 11571437 - Methods of treating cancer using PRMT5 inhibitors (2023-02-07),

4. 11214622 - Antibodies specific for DR5 and methods of use (2022-01-04),

5. 9956243 - Combination treatment for acute myeloid leukemia (AML) (2018-05-01),

6. 9926379 - Bispecific antibodies specific for FAP and DR5, antibodies specific for DR5 (2018-03-27),

7. 9486445 - Combination therapy for proliferative disorders (2016-11-08),

8. 9295669 - Combination therapy for proliferative disorders (2016-03-29),

9. 9216170 - Combination therapy for proliferative disorders (2015-12-22),

10. 8741889 - Method of treating non-small cell lung cancer and colon cancer with gamma-secretase inhibitor (2014-06-03),

11. 8709419 - Combination therapy (2014-04-29),

Title: Kathryn Elizabeth Packman: Innovator in Cancer Treatment

Introduction

Kathryn Elizabeth Packman is a prominent inventor based in Newton, MA (US). She has made significant contributions to the field of cancer treatment, holding a total of 10 patents. Her innovative approaches focus on maximizing anti-tumor activity while minimizing toxicity levels.

Latest Patents

Among her latest patents is a method for administration that provides a new dosage regimen for Compound A. This regimen is designed to maximize anti-tumor activity while maintaining acceptable toxicity levels. Another notable patent involves methods of treating cancer using PRMT5 inhibitors. This patent outlines a comprehensive approach for treating patients diagnosed with cancer by administering a therapeutically effective amount of a PRMT5 inhibitor. The methods include specific dosing schedules that ensure optimal treatment outcomes.

Career Highlights

Throughout her career, Kathryn has worked with notable companies such as Hoffmann-La Roche Inc. and Roche Glycart AG. Her experience in these organizations has allowed her to develop and refine her innovative ideas in cancer treatment.

Collaborations

Kathryn has collaborated with esteemed colleagues, including Brian Higgins and Kenneth Kolinsky. These partnerships have further enhanced her research and development efforts in the field of oncology.

Conclusion

Kathryn Elizabeth Packman is a trailblazer in the realm of cancer treatment innovations. Her patents and collaborative efforts reflect her commitment to improving patient outcomes through advanced therapeutic methods.

Profile summary based on public USPTO records.